249 related articles for article (PubMed ID: 20394719)
1. Long-term immunogenicity of influenza vaccine among the elderly: Risk factors for poor immune response and persistence.
Song JY; Cheong HJ; Hwang IS; Choi WS; Jo YM; Park DW; Cho GJ; Hwang TG; Kim WJ
Vaccine; 2010 May; 28(23):3929-35. PubMed ID: 20394719
[TBL] [Abstract][Full Text] [Related]
2. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
[TBL] [Abstract][Full Text] [Related]
3. Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant?
Skowronski DM; Tweed SA; De Serres G
J Infect Dis; 2008 Feb; 197(4):490-502. PubMed ID: 18275271
[TBL] [Abstract][Full Text] [Related]
4. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
[TBL] [Abstract][Full Text] [Related]
5. Immune response to influenza vaccination in community-dwelling Chinese elderly persons.
Hui SL; Chu LW; Peiris JS; Chan KH; Chu D; Tsui W
Vaccine; 2006 Jun; 24(25):5371-80. PubMed ID: 16713661
[TBL] [Abstract][Full Text] [Related]
6. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
7. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma.
Zuccotti G; Amendola A; Viganò A; Pariani E; Zappa A; Pogliani L; Giacomet V; Savarino A; Podestà A; Rottoli A; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2007 Sep; 25(37-38):6692-8. PubMed ID: 17697730
[TBL] [Abstract][Full Text] [Related]
8. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
[TBL] [Abstract][Full Text] [Related]
9. The immunogenicity of intradermal influenza vaccination in COPD patients.
Chuaychoo B; Wongsurakiat P; Nana A; Kositanont U; Maranetra KN
Vaccine; 2010 May; 28(24):4045-51. PubMed ID: 20412877
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
Roman F; Vaman T; Gerlach B; Markendorf A; Gillard P; Devaster JM
Vaccine; 2010 Feb; 28(7):1740-5. PubMed ID: 20034605
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
[TBL] [Abstract][Full Text] [Related]
12. Antibody response to influenza vaccine in adults vaccinated with identical vaccine strains in consecutive years.
Nabeshima S; Kashiwagi K; Murata M; Kanamoto Y; Furusyo N; Hayashi J
J Med Virol; 2007 Mar; 79(3):320-5. PubMed ID: 17245715
[TBL] [Abstract][Full Text] [Related]
13. HI responses induced by seasonal influenza vaccination are associated with clinical protection and with seroprotection against non-homologous strains.
Luytjes W; Enouf V; Schipper M; Gijzen K; Liu WM; van der Lubben M; Meijer A; van der Werf S; Soethout EC
Vaccine; 2012 Jul; 30(35):5262-9. PubMed ID: 22691431
[TBL] [Abstract][Full Text] [Related]
14. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial.
Cools HJ; Gussekloo J; Remmerswaal JE; Remarque EJ; Kroes AC
J Med Virol; 2009 May; 81(5):908-14. PubMed ID: 19319953
[TBL] [Abstract][Full Text] [Related]
15. A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza.
Kung HC; Huang KC; Kao TM; Lee YC; Chang FY; Wang NC; Liu YC; Lee WS; Liu HJ; Chen CI; Chen CH; Huang LM; Hsieh SM
Vaccine; 2010 Oct; 28(45):7337-43. PubMed ID: 20817013
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and tolerability of inactivated flu vaccine in high risk and healthy children.
Avila Aguero ML; Soriano-Fallas A; Umaña-Sauma MA; Ulloa-Gutierrez R; Arnoux S
Medicina (B Aires); 2007; 67(4):351-9. PubMed ID: 17891930
[TBL] [Abstract][Full Text] [Related]
17. Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine.
Song JY; Cheong HJ; Noh JY; Seo YB; Choi WS; Cho GJ; Hwang TG; Kim WJ
J Med Virol; 2013 Sep; 85(9):1591-7. PubMed ID: 23852684
[TBL] [Abstract][Full Text] [Related]
18. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.
Ansaldi F; Canepa P; Ceravolo A; Valle L; de Florentiis D; Oomen R; Vogel FR; Denis M; Samson SI; Icardi G
Vaccine; 2012 Apr; 30(18):2908-13. PubMed ID: 22342501
[TBL] [Abstract][Full Text] [Related]
19. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer.
Jo YM; Song JY; Hwang IS; Lee J; Oh SC; Kim JS; Kim SR; Kim WJ; Cheong HJ
J Med Virol; 2009 Apr; 81(4):722-7. PubMed ID: 19235853
[TBL] [Abstract][Full Text] [Related]
20. Serological response to influenza vaccine after hematopoetic stem cell transplantation.
Yalçin SS; Kondolot M; Albayrak N; Altaş AB; Karacan Y; Kuşkonmaz B; Aksu S; Cetin M; Göker H; Yurdakök K; Uçkan D
Ann Hematol; 2010 Sep; 89(9):913-8. PubMed ID: 20119669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
